Bin Li  Morgan Stanley

The buy side says: “Bin Li’s knowledge of the health care sector is truly impressive.”

Bin Li claims the pole position for a second straight year. One buy-side supporter credits the Morgan Stanley analyst with “total fearlessness, as he is unafraid to admit he doesn’t know something or to stick his neck out when he does.” Li urged investors to buy United Laboratories International Holdings in March 2010, at HK$5.14, on the pharmaceuticals maker’s strong growth prospects. In March 2011 the Hong Kong–based company reported that year-over-year revenue had surged 40.1 percent, to HK$6.5 billion ($998.2 million), in 2010 and gross profits were up 41.6 percent, to HK$2.57 billion. The stock had soared to HK$13.04 by the end of April 2011, a stunning 153.7 percent gain at a time when the sector was flat. Li “is among the best analysts covering the China pharmaceuticals space,” declares one loyalist.